<DOC>
	<DOCNO>NCT02339701</DOCNO>
	<brief_summary>The primary goal phase II study compare SBRT IMRT . The hypothesis arm probability change EPIC HRQOL score ( 1-year minus baseline ) less ( equal ) acceptable limit . If show either arm tolerable term patient-reported outcome ( PRO ) hypofractionated regimen consider use phase III study .</brief_summary>
	<brief_title>Stereotactic Body Radiotherapy v Intensity-modulated Radiotherapy Prostate Cancer</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<criteria>Histological confirmation prostate adenocarcinoma Low intermediate risk prostate cancer patient ( i.e . T1T2c PSA 20 Gleason score &lt; 8 ) risk pelvic node metastasis 15 % calculate Roach 's formula ECOG performance score 01 Age â‰¥ 18 History/physical examination within 2 week prior registration Able sign informedconsent Patients previous diagnosis cancer prostate cancer nonmelanoma skin cancer . Evidence distant metastasis Regional lymph node involvement Previous radical surgery ( prostatectomy ) , cryosurgery , HIFU prostate cancer Previous pelvic irradiation , prostate brachytherapy , bilateral orchiectomy Previous hormonal therapy , LHRH agonists ( e.g. , goserelin , leuprolide ) LHRHantagonists ( e.g. , degarelix ) , antiandrogens ( e.g. , flutamide , bicalutamide ) , estrogens ( e.g.DES ) , surgical castration ( orchiectomy ) Unstable angina and/or congestive heart failure require hospitalization , transmural myocardial infarction within last 6 month , acute bacterial fungal infection require intravenous antibiotic , chronic obstructive pulmonary disease exacerbation respiratory illness requiringhospitalization preclude study therapy time registration Patients receive prior chemotherapy .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>